Eris Lifesciences has allotted 22,492 equity shares under ESOP on 20 June 2024. The paid up equity share capital has increased to Rs. 13,60,75,008 (13,60,75,008 equity shares of Re.1/- each).Powered by Capital Market - Live News

The Board of ERIS Lifesciences at its meeting held on 21 May 2024 has approved composite scheme of arrangement u/s 230 to 232 read with section 66 and other applicable provisions of the Companies Act, 2013, amongst Eris Lifesciences and Eris Oaknet Healthcare and their respective Shareholders and Creditors. Powered by Capital Market - Live News

The Board of ERIS Lifesciences at its meeting held on 21 May 2024 has approved issuance of non-convertible debentures (NCDs) for an amount aggregating up to Rs 1250 crore in one or multiple series through private placement. Powered by Capital Market - Live News

Net profit of ERIS Lifesciences rose 8.47% to Rs 70.96 crore in the quarter ended March 2024 as against Rs 65.42 crore during the previous quarter ended March 2023. Sales rose 37.99% to Rs 547.27 crore in the quarter ended March 2024 as against Rs 396.59 crore during the previous quarter ended March 2023.For the full year,net profit rose 2.57% to Rs 391.98 crore in the year ended March 2024 as against Rs 382.16 crore during the previous year ended March 2023. Sales rose 19.83% to Rs 1991.30 crore in the year ended March 2024 as against Rs 1661.82 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales547.27396.59 38 1991.301661.82 20 OPM %27.1229.98 -33.8932.30 - PBDT130.55111.03 18 613.84521.73 18 PBT76.6575.90 1 431.24404.64 7 NP70.9665.42 8 391.98382.16 3 Powered by Capital Market - Live News

Net profit of ERIS Lifesciences declined 55.02% to Rs 39.51 crore in the quarter ended March 2024 as against Rs 87.84 crore during the previous quarter ended March 2023. Sales rose 7.75% to Rs 332.25 crore in the quarter ended March 2024 as against Rs 308.36 crore during the previous quarter ended March 2023.For the full year,net profit declined 24.70% to Rs 299.71 crore in the year ended March 2024 as against Rs 398.01 crore during the previous year ended March 2023. Sales rose 11.29% to Rs 1454.75 crore in the year ended March 2024 as against Rs 1307.12 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales332.25308.36 8 1454.751307.12 11 OPM %23.8936.16 -31.2038.64 - PBDT70.89112.79 -37 431.22501.58 -14 PBT41.7595.51 -56 328.83436.92 -25 NP39.5187.84 -55 299.71398.01 -25 Powered by Capital Market - Live News